Buy ENOVID Virx - SaNOtize Nitric Oxide Nasal Spray- Free Shipping
Free DeliveryWORLDWIDE EXPEDITED DELIVERY
Already tested positive?
99% Reduction in COVID-19 Viral Load
Glenmark Phase III clinical trial shows reduction in SARS-CoV-2 log viral load by 94% within 24 hours, and by more than 99% in 48 hours.
Stay Safe Everywhere
Protect yourself from viruses at work or school, during meetings or when using public transportation and flights.
Use SaNOtize NONS Daily
Enovid can be used as a proactive measure or to reduce the viral load. It kills viruses in the nasal cavity, the main "gateway" to viruses in the respiratory tract and significantly reduces the viral load in the body. Easy to use and made from natural ingredients only.
PHASE 3 CLINICAL TRIAL CONFIRMS
SANOTIZE’S TREATMENT IS 99% EFFECTIVE
On Feb 9, 2022 SaNOtize announced the completion of Phase 3 trial in India for its nitric oxide nasal spray. The trial reached primary endpoint:
Reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours
The double-blind, parallel arm, multicenter study, conducted in 306 patients in non-hospitalized adult patients. NONS was safe and well tolerated by patients. No patients experienced moderate, severe, serious Adverse Events (AE) or death in the study.
Videos About Enovid
SANOTIZE CEO ON COVID-FIGHTING NASAL SPRAY
AN INTERVIEW WITH CHRIS MILLER PHD OF SANOTIZE
A live interview by the Out of the Doldrums Youtube Channel
"The Power of NO: How a Tiny Natural Molecule Can Help Shift How We Treat Covid-19 and Other Infections While more work needs to be done, the current research into new delivery platforms for nitric oxide is extremely promising. We hope to see the molecule play an increasingly prominent role in treatment and prevention strategies for common infections – and in so doing help provide greater access to healthcare globally." Published on Jan 4th, 2023 on MedCityNews.com, By Gilly Regev and Chris Miller Click here to read the full articleRead More
"Enovid, an innovative anti-viral spray developed in Canada by an Israeli researcher and manufactured in Israel, has been proven effective in preventing viruses – including COVID-19 – from entering the body through the nasal cavity." Published: JANUARY 3, 2023 12:13 on the Jerusalem post, click to READ MORERead More
There are currently zero authorized or approved preventative COVID therapies in the U.S. but Canadian biotech SaNOtize wants to change that, charting plans to move a nasal spray into a phase 3 study as soon as October. It’s a deviation for the company that until now has been developing the nitric oxide nasal spray (NONS) as an early antiviral treatment, primarily assessing a reduction in viral load and testing time. But the takeaway from the company’s July 18 meeting with regulators was that those two markers wouldn’t be sufficient primary endpoints in a phase 3 treatment trial over a reduction...Read More
SaNOtize has raised a $24 million series B round, giving it the cash to fund its ongoing phase 3 COVID-19 prevention trial and other research into its nitric oxide nasal spray (NONS). The Vancouver-based company set up shop in 2017 to unlock the antimicrobial properties of nitric oxide. Using its nitric oxide releasing solution platform, SaNOtize sought to enable the use of the molecule in sprays, baths, lavages, gels and creams. Interest in the platform went up a gear in 2020 when COVID-19 created a pressing need for interventions capable of treating and preventing SARS-CoV-2 infection. Published by Nick Paul Taylor on Aug...Read More
Clinical Study Suggests SaNOtize Nitric Oxide Nasal Spray Is Effective at Preventing COVID-19 after High-Risk Exposure
Published on May 11, 2022 on Businesswire.com. After confirmed exposure to COVID-19, infection rate in participants (n=625) who took NONS™ was 6.4% versus 25.6% in the control group (P<0.0001). The new data build upon previously reported Phase III trial results demonstrating that a rapid reduction of viral load prevents progression to infection after COVID-19 exposure. The new study, conducted at Srinakharinwirot University in Bangkok, Thailand, found participants who took NONS after COVID-19 exposure were 75% less likely to become infected when compared to the control group, yielding a statistically significant reduction in infection rate. The study was carried out during an...Read More
SaNOtize and Glenmark Pharmaceuticals Limited has announced on February 09, 2022: Phase 3 trial reached primary endpoint and demonstrated a reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours Treatment also demonstrated, in the high-risk group (n=218), a greater proportion of patients who achieved a combination of clinical and virological cure, based on the WHO Progression Scale Median time to virological cure was 4 days in the treatment group, 8 days in the placebo group (p < 0.05). A Phase 3 clinical trial was...Read More
Outstanding Preliminary Results of A Clinical Trial Treating Moderate-To-Severe Covid-19 Patients, Conducted By Amorphical, An Israeli Biotechnology Company
Amorphical, an Israeli biotech company developing Amorphous Calcium Carbonate (ACC) has announced results of a phase II clinical trial. Amorphical’s Novel COVID-19 Amorphous Calcium Carbonate (ACC) Treatment Significantly Reduces the Risk of ICU Admission and Mortality in Interim Analysis of a Phase II Study Involving Patients Hospitalized with Moderate-to-Severe COVID-19. (NIH Clinical Trial Registration No. NCT04900337) Published by Amorphical, Ness Ziyona, Israel | January 06, 2022 https://newsdirect.com/news/outstanding-preliminary-results-of-a-clinical-trial-treating-moderate-to-severe-covid-19-patients-conducted-by-amorphical-an-israeli-biotechnology-company-973592489 Read more on the Jerusalem Post (published December 22, 2021): https://www.jpost.com/health-and-wellness/coronavirus/article-689543Read More
SaNOtize reports that NONS sales in Q3 2021 were $5M and are projected to exceed $9M by the end of 2021. SaNOtize anticipates 2022 revenues will be $70-100M - the timing of approvals in various countries is a key driver of sales volume. With healthy contribution margins, the company believes it could be cash flow positive by the end of 2022. The company is now raising additional funds through OurCrowd platform; To read more about this investment opportunity, here is a link to SaNOtize's company page.Read More
U.K. clinical trials for Vancouver’s SaNOtize have confirmed that its nasal spray reduced SARS-CoV-2 log viral load by more than 95 per cent in infected participants within 24 hours of treatment, and by more than 99 per cent in 72 hours. While the product is set to sell over the counter in Israel and New Zealand pharmacies, Dr. Gilly Regev says Health Canada sees their product as a drug and not a medical device, hindering the ability for SaNOtize to be available to the Canadian market sooner rather than later.Read More
Tyler Durden is reviewing the recent results of SaNOtize clinical study in the UK, click here to read the articleRead More
Renée Reardin is writing about SaNOtize’s nasal spray and provide some useful information about clinical trails and the potential of enovid in fighting covid-19 Click here to read more at Best HealthRead More
SaNOtize commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets
SaNOtize inks agreement with Indian biotech Glenmark to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets Click here to read more at Businesswire.comRead More
Enovid is approved by the Israeli MOH to be sold in pharmacies across Israel. The product which was developed by Canadian Bio company SaNOtize is manufactured in Israel. This website allows you to purchase enovid online. We ship worldwide with 3-5 days delivery by DHL. You can buy Enovid online and have SaNOtize NANOS nasal spray with you within days. Enovid is offered here at 2-PACK or 3-PACK. You can read more about Enovid at SaNOtize website: https://sanotize.com/enovid/ From the Press: Canadian Biotech Progresses COVID-19 Nasal Spray, Claims Promise Against Variants (published on scrip.pharmaintelligence.informa.com, 30 June, 21): The Vancouver, Canada-based biotech...Read More